“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.

If the July 23 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee is any indication, FDA appears years away from changing approval standards for generics of drugs with complex dosage forms.